Design Therapeutics, Inc. (DSGN) · Nov 4, 2026 · Earnings

Design Therapeutics earnings beat, but trial milestones stay unchanged

Beat — EPS -$0.32 vs ~$0.38 loss consensus

Design Therapeutics earnings modestly beat the EPS consensus, while DT-216P2 milestones and the 2027 data timeline remain unchanged.

Design Therapeutics is a clinical-stage biotech trying to move DT-216P2 from encouraging early Friedreich ataxia data toward a registrational program, while advancing earlier-stage DM1, corneal-disease and Huntington’s disease programs. Its May 2026 data already supported a registrational path, and the company had previously set the Q4 2026 planning update and Q1 2027 12-week data as the next key milestones.

The quarter cleared the limited earnings bar. Reported loss per share was $0.32, versus a published consensus estimate of about $0.38, a modest beat; the comparison is meaningful but not a major change to a development-stage biotech with no product revenue.

Q3 2026Q3 2025Consensus
Net loss (Financial Results)$20.3M$17.0M
Net loss per share (Statements of Operations)$(0.32)$(0.30)$(0.38)
R&D expense (Financial Results)$16.9M$14.6M
Cash and securities (Balance Sheets)$208.6M

The actual business update is confirmation, not acceleration. RESTORE-FA remains underway, with the registrational-plan update still expected in Q4 2026 and 12-week treatment data still expected in Q1 2027. 〔0〕 That timing was already public from the prior quarter, so this filing does not materially improve the clinical outlook.

Spending is rising as the pipeline advances, while the cash cushion remains substantial. Quarterly R&D expense increased to $16.9 million from $14.6 million, and nine-month net loss reached $58.1 million versus $53.8 million a year earlier. Cash and securities declined from $219.8 million at year-end to $208.6 million at September 30, but the balance still supports continued clinical execution.

Bottom line: This is a narrow earnings beat with no new clinical evidence and no change to the key DT-216P2 timetable. It modestly supports execution, but the company’s core story still depends on the upcoming registrational-plan update and 2027 data.

What to watch next

Q4 registrational-plan update for DT-216P2

Original filing on SEC EDGAR

Design Therapeutics earnings beat, but trial milestones stay unchanged | DSGN Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.